Login to Your Account



Biogen Receives Approval For Amevive, Signs Deal With IDEC

By Brady Huggett


Monday, February 3, 2003
Ushering in what Biogen Inc. CEO and chairman James Mullen called "an exciting time for us and hopefully an exciting time for our investors," the FDA approved Biogen's Amevive for psoriasis, giving Biogen the first biologic treatment for that indication. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription